Joseph P Buyniski

US Patent:

43573304, Nov 2, 1982

Filed:

Jul 30, 1981

Appl. No.:

6/288639

Inventors:

James S. Fleming - Manlius NY
Joseph P. Buyniski - Syracuse NY

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 31625

US Classification:

424232

Abstract:

Supra-additive blood platelet antiaggregation activity is observed with anagrelide in combination with those non-steroidal anti-inflammatory agents which are inhibitors of platelet cyclooxygenase. The supra-additive effects of such combinations make possible new compositions and methods for both therapeutic and prophylactic treatment of thrombosis and other disorders associated with blood platelet aggregation.

US Patent:

40187675, Apr 19, 1977

Filed:

May 22, 1975

Appl. No.:

5/579763

Inventors:

Joseph Paul Buyniski - Syracuse NY
Alex Michael Jelenevsky - Greensboro NC
Ronald Leslie Buchanan - Fayetteville NY

Assignee:

Bristol-Myers Company - New York NY

International Classification:

C07D41306
C07D20994
C07D40106
C07D40306

US Classification:

2602472A

Abstract:

A series of 5-endo-(1-naphthoyloxy)-N-[amino-(lower)alkyl]bicyclo[2. 2. 1]heptane-2,3-di -endo-carboxylic acid imides have been found to possess unique prophylactic and therapeutic activity as anti-arrhythmia agents. An example of such a compound possessing excellent activity is 5-endo-(1-naphthoyloxy)-N-(3-dimethylaminopropyl)bicyclo[2. 2. 1]heptane-2,3 -di-endo-carboxylic acid imide hydrochloride.

US Patent:

43394396, Jul 13, 1982

Filed:

Jan 19, 1981

Appl. No.:

6/225945

Inventors:

Joseph P. Buyniski - Syracuse NY
Robert L. Cavanagh - Manlius NY
Maxwell Gordon - Syracuse NY

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3700

US Classification:

424177

Abstract:

Enhanced antiulcer activity is obtained in warm-blooded animals by the concomitant administration of the histamine H. sub. 2 -receptor antagonist, etintidine, and the pepsin complexing agent, pepstatin. Concomitant administration of the two entities reduces the amount of etintidine necessary for effective treatment, thereby decreasing its side effect liability.

US Patent:

44329806, Feb 21, 1984

Filed:

Aug 19, 1982

Appl. No.:

6/409736

Inventors:

James S. Fleming - Manlius NY
Joseph P. Buyniski - Syracuse NY

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61U 3119
A61U 31505

US Classification:

424251

Abstract:

Supra-additive blood platelet antiaggregation activity is observed with anagrelide in combination with those non-steroidal anti-inflammatory agents which are inhibitors of platelet cyclooxygenase. The supra-additive effects of such combinations make possible new compositions and methods for both therapeutic and prophylactic treatment of thrombosis and other disorders associated with blood platelet aggregation.

US Patent:

44447779, Apr 24, 1984

Filed:

Aug 5, 1983

Appl. No.:

6/520872

Inventors:

James S. Fleming - Manlius NY
Joseph P. Buyniski - Syracuse NY

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3147
A61K 31415

US Classification:

424258

Abstract:

Supra-additive blood platelet antiaggregation activity is observed with anagrelide in combination with those non-steroidal anti-inflammatory agents which are inhibitors of platelet cyclooxygenase. The supra-additive effects of such combinations make possible new compositions and methods for both therapeutic and prophylactic treatment of thrombosis and other disorders associated with blood platelet aggregation.

US Patent:

43224270, Mar 30, 1982

Filed:

Apr 16, 1981

Appl. No.:

6/254821

Inventors:

Joseph P. Buyniski - Syracuse NY
Anthony W. Pircio - Manlius NY

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3140
A61K 31485

US Classification:

424260

Abstract:

A method of producing analgesia by the simultaneous or sequential administration of butorphanol and zomepirac and compositions comprising butorphanol and zomepirac which provide enhanced (synergistic) analgetic potencies.

US Patent:

46005781, Jul 15, 1986

Filed:

May 11, 1984

Appl. No.:

6/609269

Inventors:

Anthony W. Pircio - Manlius NY
Joseph P. Buyniski - Syracuse NY
William T. Comer - Greenwich CT

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3174

US Classification:

424 78

Abstract:

Oral administration of particular quaternized vinylimidazole-ethylene glycol dimethacrylate copolymers inhibits diarrhea.

US Patent:

42776058, Jul 7, 1981

Filed:

Mar 7, 1980

Appl. No.:

6/128329

Inventors:

Joseph P. Buyniski - Syracuse NY
John W. Hooper - Pierrefonds, CA
Gary M. F. Lim - Candiac, CA

Assignee:

Bristol-Myers Company - New York NY

International Classification:

C07D22128
A61K 31485

US Classification:

546 74

Abstract:

3-Hydroxy-7-oxomorphinans and 3-hydroxy-7-oxoisomorphinans, optionally substituted on the 17-nitrogen atom, are potent, orally active antidiarrheal agents.